title: Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom.
abstract: OBJECTIVE
  To undertake the first substantial clinical study of breast radiotherapy toxicity in BRCA1 and BRCA2 mutation carriers in the United Kingdom.
  
  
  METHODS
  Acute and late radiation effects were evaluated in a retrospective study of 55 BRCA1 and BRCA2 mutation carriers treated with radiotherapy for breast cancer at four centers between 1983 and 2002. Individual matching with controls who had sporadic breast cancer was undertaken for age at diagnosis, time since completion of radiation, and treatment variables. Detailed assessments were undertaken by one examiner. Median follow-up was 6.75 years for carriers and 7.75 years for controls. Rates of late events (rib fractures, lung fibrosis, necrosis of soft tissue/bone, and pericarditis) as well as LENT-SOMA scores and clinical photography scores of breast size, shape, and skin telangiectasia were the primary end points.
  
  
  RESULTS
  No increase in clinically significant late toxicity was seen in the mutation carriers.
  
  
  CONCLUSIONS
  These data add substantial weight to the evidence that the outcomes in the treated breast from radiotherapy in women with BRCA1 or BRCA2 mutations are comparable with those in women with sporadic breast cancer.
authors.affiliation: Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK. Susan.Shanley@rmh.nhs.uk
authors.forename: Susan
authors.initials: S
authors.lastname: Shanley
authors.forename: Kate
authors.initials: K
authors.lastname: McReynolds
authors.forename: Audrey
authors.initials: A
authors.lastname: Ardern-Jones
authors.forename: Roger
authors.initials: R
authors.lastname: Ahern
authors.forename: Indrajit
authors.initials: I
authors.lastname: Fernando
authors.forename: John
authors.initials: J
authors.lastname: Yarnold
authors.forename: Gareth
authors.initials: G
authors.lastname: Evans
authors.forename: Diana
authors.initials: D
authors.lastname: Eccles
authors.forename: Shirley
authors.initials: S
authors.lastname: Hodgson
authors.forename: Sue
authors.initials: S
authors.lastname: Ashley
authors.forename: Linda
authors.initials: L
authors.lastname: Ashcroft
authors.forename: Andrew
authors.initials: A
authors.lastname: Tutt
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Bancroft
authors.forename: Susan
authors.initials: S
authors.lastname: Short
authors.forename: Gerald
authors.initials: G
authors.lastname: Gui
authors.forename: Lester
authors.initials: L
authors.lastname: Barr
authors.forename: Andrew
authors.initials: A
authors.lastname: Baildam
authors.forename: Anthony
authors.initials: A
authors.lastname: Howell
authors.forename: Gavin
authors.initials: G
authors.lastname: Royle
authors.forename: Lori
authors.initials: L
authors.lastname: Pierce
authors.forename: Douglas
authors.initials: D
authors.lastname: Easton
authors.forename: Rosalind
authors.initials: R
authors.lastname: Eeles
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy*; D016022:Case-Control Studies; D005260:Female; D005500:Follow-Up Studies; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D018095:Germ-Line Mutation; D006579:Heterozygote; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011878:Radiotherapy; D012189:Retrospective Studies; D016896:Treatment Outcome; D006113:United Kingdom / Q000453:epidemiology